CC BY 4.0 · Journal of Child Science 2022; 12(01): e224-e227
DOI: 10.1055/s-0042-1758871
Original Article

Comparison of Clinical Outcome between Immunocompetent and Immunocompromised Children Aged 1 to 12 Years Admitted with Acute COVID-19 Infection – A Retrospective Review

1   Department of Paediatrics, VMMC & Safdarjung Hospital, New Delhi, India
,
Ritabrata Roy Chowdhury
1   Department of Paediatrics, VMMC & Safdarjung Hospital, New Delhi, India
,
Aditya Dabas
1   Department of Paediatrics, VMMC & Safdarjung Hospital, New Delhi, India
,
Sumit Mehndiratta
1   Department of Paediatrics, VMMC & Safdarjung Hospital, New Delhi, India
,
1   Department of Paediatrics, VMMC & Safdarjung Hospital, New Delhi, India
,
Rani Gera
1   Department of Paediatrics, VMMC & Safdarjung Hospital, New Delhi, India
› Author Affiliations

Abstract

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created havoc in adults and children. Immunocompromised children are considered a high-risk group for the extreme manifestation of coronavirus disease 2019 (COVID-19) infection. There are conflicting reports on the outcome of SARS-CoV-2 disease in immunocompromised children. We aimed to find the difference in clinical outcomes of COVID-19 infection between immunocompetent and immunocompromised children. This includes a retrospective chart review of children admitted with COVID-19 infection in a tertiary care pediatric hospital in Northern India from March 1, 2021, to May 31, 2021. There were 35 COVID-19-positive children aged 1 to 12 years admitted during the study period. The study participants were divided into two groups: immunocompetent and immunocompromised patients. The clinical features, laboratory parameters, treatment needs, and outcomes in both groups were compared. Among 35 patients enrolled, 17 were immunocompromised and 18 were immunocompetent. The median duration of hospital stay, clinical features, laboratory parameters, severity of illness, treatment needs, and outcomes were comparable between the two groups. Immunocompromised children are not at a higher risk of severe COVID-19 manifestation compared to immunocompetent children.



Publication History

Received: 03 December 2021

Accepted: 15 October 2022

Article published online:
05 December 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 World Health Organization. WHO coronavirus (COVID-19) Dashboard
  • 2 Zhou Y, Yang Q, Chi J. et al. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: a systematic review and meta-analysis. Int J Infect Dis 2020; 99: 47-56
  • 3 Vabret N, Britton GJ, Gruber C. et al; Sinai Immunology Review Project. Immunology of COVID-19: current state of the science. Immunity 2020; 52 (06) 910-941
  • 4 Qin C, Zhou L, Hu Z. et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 2020; 71 (15) 762-768
  • 5 Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 2020; 20 (05) 533-534
  • 6 Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science 2020; 368 (6490): 473-474
  • 7 Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. HLH Across Specialty Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395 (10229): 1033-1034
  • 8 Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323 (13) 1239-1242
  • 9 Liang W, Guan W, Chen R. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020; 21 (03) 335-337
  • 10 Mehta V, Goel S, Kabarriti R. et al. Case fatality rate of cancer patients with COVID-19 in a New York Hospital System. Cancer Discov 2020; 10 (07) 935-941
  • 11 Belsky JA, Tullius BP, Lamb MG, Sayegh R, Stanek JR, Auletta JJ. COVID-19 in immunocompromised patients: a systematic review of cancer, hematopoietic cell and solid organ transplant patients. J Infect 2021; 82 (03) 329-338
  • 12 Simioli F, Martino M, Annunziata A, Carannante N, Fiorentino G. Therapeutic approach for severe COVID-19 and immunocompromised patients. A case series. Respir Med Case Rep 2021; 33: 101397
  • 13 Fung M, Babik JM. COVID-19 in immunocompromised hosts: what we know so far. Clin Infect Dis 2021; 72 (02) 340-350
  • 14 Kuderer NM, Choueiri TK, Shah DP. et al; COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 2020; 395 (10241): 1907-1918
  • 15 Robilotti EV, Babady NE, Mead PA. et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med 2020; 26 (08) 1218-1223
  • 16 Brar G, Pinheiro LC, Shusterman M. et al. COVID-19 severity and outcomes in patients with cancer: a matched cohort study. J Clin Oncol 2020; 38 (33) 3914-3924